schedule of services
BCVG has capabilities to drive all aspects of the transaction process:
Due Diligence
Asset identification and competitive assessment
Scientific, clinical & regulatory review
Quality and reimbursement analysis
Channel checks and KOL perspectives
Financial modeling and forecasting
Transaction Services
Investor and partner identification and outreach
Pitch deck and marketing material preparation
Term sheet construction
Deal negotiations
Contract reviews
How we leverage
integrated Insights™
BCVG believes input and perspectives from all operational functions is essential for due diligence, positioning assets for sale and valuating assets for purchase.
This holistic approach separates BCVG from many other consulting firms that focus on a single business discipline.
WHAT OUR CLIENT partners ARE SAYING
Kevin
CEO, Orthopaedic OEM
BCVG's thorough, cross-functional diligence guided our decision to successfully acquire a significant new asset. Their approach to partnering with our internal team was flexible and seamless.
Peter
Managing Partner, PE Firm
BCVG's domain expertise and insights guided us, fortunately, NOT to invest in an asset. Their predictions regarding changes in the regulatory and competitive landscape all came true, saving us hundreds of millions of dollars on what would have become a terrible investment.
Stephanie
Sr VP R&D, Orthopaedic OEM
BCVG's understanding of the market, FDA regulations, and competency of industry players governed the design of multiple product development agreements with tissue banks and other business to business suppliers.
DEAL sheet
Transaction Support for Strategics
$500MM+
acquisition of a
private U.S. spinal implant firm
$400MM+
acquisition of private U.S. biomaterial
implant firm
$50MM+
acquisition of a
private U.S. biotech company
$50MM+
acquisition of a public OUS orthobiologic business
$30MM+
acquisition of a public US orthobiologic business
Transaction Support for Private Equity
$350MM+
acquisition of a
private U.S. biomaterial firm
$150MM+
acquisition of a
U.S. spine
company
$100MM+
acquisition of a
U.S. spine
company
$50MM+
acquisition of an
orthopaedic implant
firm
Product Development, Distribution and License Agreements
Allograft-based regeneration products for orthopaedic firms
Collagen-based regeneration products for orthopaedic firms
Bioactive factor-based regeneration products for orthopaedic firms
Cell-based regeneration products for orthopaedic and wound care firms
Allograft-and xenograft-based products for wound care firms